Elysium Health is a Consumer Longevity company founded in 2014 and based in New York, United States. It has raised $71.2M in total funding, most recently a Venture.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.

Elysium Health launches Creatine+, a supplement combining creatine, HMB and pomegranate compounds targeting strength, recovery and healthy aging.
Elysium's flagship daily supplement, launched in 2015, designed to increase and sustain levels of NAD+, a coenzyme central to cellular metabolism that declines with age. Basis combines nicotinamide riboside, an NAD+ precursor, with pterostilbene, a polyphenol related to resveratrol. It is sold direct-to-consumer on a subscription model and is positioned around cellular health and healthy aging. The company has emphasized publishing human clinical-trial data on the product.
A collagen system launched in March 2025, marketed as a four-in-one product that supports collagen production while addressing several root causes of collagen decline, including aged fibroblasts and falling NAD+ and hyaluronic-acid levels. It pairs collagen-building ingredients with an NAD+ boost and is aimed at skin, hair, and connective-tissue aging. Like Basis, it is sold direct-to-consumer and developed with the company's scientific advisers.
3 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.